Ibrance, Prevnar 13 Q2 Sales Validate Pfizer's R&D Investments
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel products help the company beat consensus estimates for the quarter, and the pharma giant pointed to immuno-oncology and PCSK9 as investments that will provide greater returns in the future. Additional acquisitions and a potential split remain on the table, execs say.
You may also be interested in...
Pfizer Oncology Strategy: An Investment Starts To Pay Off
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.